Can a JAK inhibitor calm chronic hives? new trial aims to find out
NCT ID NCT06795373
First seen Dec 10, 2025 · Last updated May 24, 2026 · Updated 26 times
Summary
This study tests whether ritlecitinib, a drug already approved for another condition, can safely reduce hives and itching in people with chronic spontaneous urticaria (hives lasting over 6 weeks). Participants take the drug for 12 weeks and track their symptoms daily. The trial was withdrawn before enrolling anyone, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
Conditions
Explore the condition pages connected to this study.